These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 7642857)

  • 1. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Holmes DR; Bates ER; Kleiman NS; Sadowski Z; Horgan JH; Morris DC; Califf RM; Berger PB; Topol EJ
    J Am Coll Cardiol; 1995 Sep; 26(3):668-74. PubMed ID: 7642857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study.
    Berger PB; Holmes DR; Stebbins AL; Bates ER; Califf RM; Topol EJ
    Circulation; 1997 Jul; 96(1):122-7. PubMed ID: 9236426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee.
    Topol EJ; Armstrong P; Van de Werf F; Kleiman N; Lee K; Morris D; Simoons M; Barbash G; White H; Califf RM
    J Am Coll Cardiol; 1992 May; 19(6):1123-8. PubMed ID: 1564212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Langer A; Krucoff MW; Klootwijk P; Veldkamp R; Simoons ML; Granger C; Califf RM; Armstrong PW
    J Am Coll Cardiol; 1995 Jun; 25(7):1552-7. PubMed ID: 7759706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
    Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM
    Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Van de Werf F; Topol EJ; Lee KL; Woodlief LH; Granger CB; Armstrong PW; Barbash GI; Hampton JR; Guerci A; Simes RJ
    JAMA; 1995 May 24-31; 273(20):1586-91. PubMed ID: 7745771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies.
    Barbash GI; Birnbaum Y; Bogaerts K; Hudson M; Lesaffre E; Fu Y; Goodman S; Houbracken K; Munsters K; Granger CB; Pieper K; Califf RM; Topol EJ; Van De Werf F
    Circulation; 2001 Feb; 103(7):954-60. PubMed ID: 11181469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial.
    White HD; Barbash GI; Califf RM; Simes RJ; Granger CB; Weaver WD; Kleiman NS; Aylward PE; Gore JM; Vahanian A; Lee KL; Ross AM; Topol EJ
    Circulation; 1996 Oct; 94(8):1826-33. PubMed ID: 8873656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators
    N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials.
    Hudson MP; Granger CB; Topol EJ; Pieper KS; Armstrong PW; Barbash GI; Guerci AD; Vahanian A; Califf RM; Ohman EM
    Circulation; 2001 Sep; 104(11):1229-35. PubMed ID: 11551872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
    Reiner JS; Lundergan CF; van den Brand M; Boland J; Thompson MA; Machecourt J; Py A; Pilcher GS; Fink CA; Burton JR
    J Am Coll Cardiol; 1994 Nov; 24(6):1439-44. PubMed ID: 7930273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
    Labinaz M; Sketch MH; Stebbins AL; DeFranco AC; Holmes DR; Kleiman NS; Betriu A; Rutsch WR; Vahanian A; Topol EJ; Califf RM
    Am J Cardiol; 1996 Dec; 78(12):1338-44. PubMed ID: 8970403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction.
    Hasdai D; Califf RM; Thompson TD; Hochman JS; Ohman EM; Pfisterer M; Bates ER; Vahanian A; Armstrong PW; Criger DA; Topol EJ; Holmes DR
    J Am Coll Cardiol; 2000 Jan; 35(1):136-43. PubMed ID: 10636271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
    Metz BK; White HD; Granger CB; Simes RJ; Armstrong PW; Hirsh J; Fuster V; MacAulay CM; Califf RM; Topol EJ
    J Am Coll Cardiol; 1998 Jun; 31(7):1493-8. PubMed ID: 9626825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries.
    Cox JL; Lee E; Langer A; Armstrong PW; Naylor CD
    CMAJ; 1997 Feb; 156(4):497-505. PubMed ID: 9054819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: a comparison of thrombolytic therapy and primary angioplasty.
    Stone GW; Grines CL; Browne KF; Marco J; Rothbaum D; O'Keefe J; Hartzler GO; Overlie P; Donohue B; Chelliah N
    J Am Coll Cardiol; 1995 Jul; 26(1):66-72. PubMed ID: 7797777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries.
    Holmes DR; Califf RM; Topol EJ
    J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):10S-17S. PubMed ID: 7775708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial.
    Holmes DR; Califf RM; Van de Werf F; Berger PB; Bates ER; Simoons ML; White HD; Thompson TD; Topol EJ
    Lancet; 1997 Jan; 349(9045):75-8. PubMed ID: 8996417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.